IV agent selection: hypertensive emergency and rate control in atrial fibrillation

Name: IV Agent Selection: Hypertensive Emergency & AF Rate Control — Helix Anesthesia
Creator: Anastasia Jackson
Published: 2026-09-26

A point-of-care guide to choosing the right intravenous drug — built around the 2025 AHA/ACC hypertensive-emergency drug list and the 2023 ACC/AHA acute rate-control agents.

Published September 26, 2026 · Last reviewed September 26, 2026 · Written by Anastasia Jackson, DNAP, CRNA

Every clinical claim on this page is cited to its source below. How we source clinical content.

The short answer

In a hypertensive emergency (BP >180/120 mm Hg with acute target-organ damage), the 2025 AHA/ACC guideline favors short-acting, titratable IV infusions and matches the agent to the comorbidity: esmolol or labetalol first in aortic dissection, clevidipine/nitroglycerin/nitroprusside in pulmonary edema (beta blockers contraindicated), and nicardipine or clevidipine for most other presentations. For acute rate control in atrial fibrillation, IV beta blockers or non-dihydropyridine calcium channel blockers (diltiazem/verapamil, only if EF >40%) are first-line, with digoxin, magnesium, or amiodarone as adjuncts or fall-backs. When both problems coexist, esmolol appears on both lists: it is a preferred agent for acute aortic dissection and for perioperative hypertension, and IV beta blockers are Class 1 for acute AF rate control — provided the patient is not in decompensated heart failure. Landiolol is indicated for short-term reduction of ventricular rate; it does not appear in the guideline’s IV antihypertensive tables.

Key takeaways

Severe hypertension without acute organ damage is not an emergency. The 2025 AHA/ACC guideline states these patients should not receive aggressive short-term lowering or parenteral therapy — restart or intensify oral agents instead.¹
Match the IV drug to the target organ. The guideline provides a comorbidity-specific table: esmolol/labetalol for dissection, clevidipine/nitroglycerin/nitroprusside for pulmonary edema, nicardipine for most others.¹
Nicardipine beats labetalol, clevidipine beats nicardipine — for speed. Trials cited by the guideline found IV nicardipine more effective than labetalol at reaching short-term BP target, and clevidipine faster than nicardipine.¹
AF acute rate control is a Class 1 recommendation for beta blockers or non-DHP CCBs — but verapamil/diltiazem only if EF >40%.²
Non-DHP CCBs are Class 3 (Harm) in moderate–severe LV systolic dysfunction. This is the single most important safety line where the two topics collide.²
Beta-1 selectivity matters. A meta-analysis found super-selective beta-1 blockers (landiolol) superior to comparators (diltiazem and digoxin, 2 studies) for achieving target heart rate, whereas selective beta-1 blockers (metoprolol, esmolol) were inferior to diltiazem.⁸

Why these two topics belong on the same page

A patient can present with both problems at once — atrial fibrillation with a rapid ventricular response driving, or coexisting with, a severe blood-pressure elevation. The IV drawer is shared: beta blockers and, in some settings, calcium channel blockers appear on both the hypertensive-emergency list and the rate-control list. The decision that keeps a clinician safe in both is the same one — is there decompensated heart failure or moderate-to-severe LV systolic dysfunction? — because that feature makes esmolol contraindicated on the hypertensive-emergency list and makes IV nondihydropyridine calcium channel blockers a Class 3 (Harm) recommendation on the rate-control list.^1,2

This is in the app, with the calculators and the drug library — free tier, no card. Get it →

Hypertensive emergency: the principles before the drug

The 2025 AHA/ACC guideline defines a hypertensive emergency as a severe BP elevation (>180/120 mm Hg) with evidence of acute target-organ damage — commonly acute heart failure/pulmonary edema, neurologic events (encephalopathy, intracerebral hemorrhage, ischemic stroke), and acute kidney injury, with aortic dissection the least common presentation.¹ In-hospital mortality is roughly 10%, with a 1-year cardiovascular morbidity and mortality of 20% to 30%.^1,7

The most common overtreatment error. Patients with severe hypertension without acute target-organ damage (previously “hypertensive urgency”) should not receive aggressive short-term BP lowering or parenteral drugs. The guideline recommends reinstituting or intensifying oral antihypertensives, preferably in the outpatient setting.¹

Several principles shape agent selection:¹

There is no RCT evidence that antihypertensive drugs reduce morbidity or mortality in hypertensive emergencies, and no high-quality RCT establishes a superior first-line class. Selection is pharmacologic reasoning, not trial-proven hierarchy.
Short-acting, titratable IV infusions are preferred in the ICU to achieve rapid control while avoiding large BP swings.
Avoid overshoot. In long-standing hypertension, autoregulation is shifted; rapid correction to “normal” can cause vital-organ hypoperfusion.
Comparative speed: IV nicardipine reached short-term targets more effectively than labetalol, and clevidipine produced faster BP reduction than nicardipine.

The 2025 AHA/ACC intravenous drug list

The following agents are drawn from Table 26 of the guideline (current corrected version). Doses are reproduced as published; cautions are abridged.¹

Class / Drug	Usual dose range	Key cautions
Nicardipine (DHP CCB)	Initial 5 mg/h, ↑ every 5 min by 2.5 mg/h to max 15 mg/h	Contraindicated in advanced aortic stenosis. No dose adjustment for age ≥65 y. No negative inotropic/chronotropic effect.
Clevidipine (DHP CCB)	Initial 1–2 mg/h, doubling every 90 s until BP near target, then ↑ <double every 5–10 min; max 21 mg/h; max duration 72 h	Contraindicated with soy/egg allergy and defective lipid metabolism (pathologic hyperlipidemia, lipoid nephrosis, acute pancreatitis). No negative inotropic/chronotropic effect; reduced reflex tachycardia.
Sodium nitroprusside (NO-dependent vasodilator)	Initial 0.3–0.5 mcg/kg/min; ↑ by 0.5 mcg/kg/min every 5 min; max 10 mcg/kg/min; shortest possible duration	Intra-arterial BP monitoring advised. Avoid in acute cerebrovascular disease unless no alternative. Cyanide/thiocyanate toxicity risk at ≥3 mcg/kg/min and/or ≥3 d, worse in hepatic/renal impairment.
Nitroglycerin (NO-dependent vasodilator)	Initial 5 mcg/min; ↑ by 5 mcg/min every 3–5 min; max 200 mcg/min	Use only in acute coronary syndrome and/or acute pulmonary edema. Avoid if volume-depleted. Tachyphylaxis with extended use.
Hydralazine (direct vasodilator)	Initial 10 mg slow IV (max initial 20 mg); repeat every 4–6 h; up to 200 mg/24 h	Onset 10–30 min, effect lasts 2–4 h. Undesirable first-line agent for most, given unpredictable response and prolonged action.
Esmolol (beta-1–selective antagonist)	Load 500–1,000 mcg/kg/min over 1 min, then 50 mcg/kg/min infusion; repeat bolus and ↑ by 50 mcg/kg/min to max 300 mcg/kg/min	Contraindicated with concurrent beta blockade, bradycardia, or decompensated HF. Higher doses may block beta-2 and affect reactive airway/obstructive lung disease.
Labetalol (combined alpha-1 / nonselective beta antagonist)	0.3–1.0 mg/kg (max 20 mg) slow IV at 10-min intervals, or 0.4–1.0 mg/kg/h infusion up to 3 mg/kg/h; up to 300 mg/24 h¹	Contraindicated in reactive airway/obstructive lung disease. Especially useful in hyperadrenergic states. May worsen HF; avoid in 2nd/3rd-degree block or bradycardia.
Phentolamine (nonselective alpha antagonist)	5 mg IV bolus; repeat every 10 min as needed; up to 50 mg/24 h	For catecholamine-excess crises (pheochromocytoma, MAOI interactions, cocaine/amphetamine, clonidine withdrawal).
Fenoldopam (dopamine-1 agonist)	Initial 0.1–0.3 mcg/kg/min; ↑ by 0.05–0.1 mcg/kg/min every 15 min; max 1.6 mcg/kg/min	Contraindicated with raised intraocular pressure (glaucoma) or raised ICP, and sulfite allergy.
Enalaprilat (ACE inhibitor)	Initial 1.25 mg over 5 min; ↑ up to 5 mg every 6 h; up to 50 mg/24 h	Contraindicated in pregnancy; avoid in acute MI and bilateral renal artery stenosis. Best for high-renin states. Slow onset (~15 min), unpredictable response.

Matching the IV agent to the comorbidity

The guideline’s second table pairs each clinical scenario with preferred IV agents. This is the practical core of agent selection.¹

Clinical setting	Preferred IV agent(s)	Key point
Acute aortic dissection	Esmolol, labetalol	Lower SBP to ≤120 mm Hg within 20 min. Beta blockade must precede any vasodilator (e.g., nicardipine, nitroprusside) to prevent reflex tachycardia/inotropy.
Acute pulmonary edema	Clevidipine, nitroglycerin, nitroprusside	Beta blockers are contraindicated.
Acute coronary syndrome	Esmolol, labetalol, nicardipine, nitroglycerin	Nitrates with PDE-5 inhibitors → profound hypotension. Beta-blocker contraindications include LV failure with pulmonary edema, HR <60, SBP <100, poor perfusion, high-grade block, reactive airways.
Acute kidney injury	Clevidipine, fenoldopam, nicardipine	—
Eclampsia / preeclampsia	Hydralazine, labetalol, nicardipine, nifedipine	ACE inhibitors, ARBs, renin inhibitors, and nitroprusside are contraindicated.
Perioperative hypertension	Clevidipine, esmolol, nicardipine, nitroglycerin	Most frequent during anesthesia induction and airway manipulation.
Catecholamine excess (pheochromocytoma, post-CEA)	Clevidipine, nicardipine, phentolamine	Requires rapid BP lowering.
Acute intracerebral hemorrhage	Clevidipine, nicardipine, esmolol, labetalol, hydralazine	Follow stroke-specific BP targets.
Acute ischemic stroke	Clevidipine, nicardipine, esmolol, labetalol, hydralazine	Follow stroke-specific BP targets.

Acute rate control in atrial fibrillation: the IV agents

For a hemodynamically stable patient with AF and a rapid ventricular response, the 2023 ACC/AHA/ACCP/HRS guideline sets a clear hierarchy.²

Recommendation	COR / LOE	Detail
Beta blockers or non-DHP CCBs (verapamil, diltiazem; only if EF >40%)	1 (B-R)	First-line for acute rate control in the hemodynamically stable patient.
Digoxin	2a (B-R)	Can be considered when beta blockers and non-DHP CCBs are ineffective or contraindicated — alone or in combination.
IV magnesium (adjunct)	2a (A)	Reasonable added to standard measures to achieve and maintain rate control.
IV amiodarone	2b (B-NR)	May be considered in critically ill and/or decompensated HF when beta blockers and non-DHP CCBs are ineffective or contraindicated.
IV non-DHP CCBs in moderate/severe LV systolic dysfunction	3: Harm (B-NR)	Should NOT be administered, with or without decompensated HF.

Onset speed favors the calcium channel blocker in the emergency setting. In one ED RCT of 150 patients randomized to IV diltiazem, digoxin, or amiodarone, rate control was achieved in 90% of the diltiazem group versus 74% for both digoxin and amiodarone, and the time to control was significantly shorter with diltiazem.² IV diltiazem also reduced heart rate within 5 minutes versus roughly 3 hours for digoxin in a separate randomized comparison.² In the 2024 ESC guideline, IV amiodarone, landiolol, or digoxin can be used in selected patients who are hemodynamically unstable or have severely impaired LVEF.³ The 2025 AHA ACLS guideline calls for immediate electrical cardioversion when instability is attributable to AF, and states that IV amiodarone can be useful for rate control in critically ill patients.⁵

The reduced-EF and heart-failure crossover

This is where the two lists conflict most dangerously. A non-dihydropyridine calcium channel blocker (verapamil, diltiazem) is first-line for AF rate control when EF >40%, but is a Class 3 (Harm) recommendation in moderate-to-severe LV systolic dysfunction.² Its dihydropyridine cousins (nicardipine, clevidipine) remain acceptable for blood-pressure control because they lack the negative inotropic/chronotropic effect.¹

Beta blockers (for all LVEF) and diltiazem/verapamil (for LVEF >40%) are preferred over digoxin for acute rate control because of their more rapid onset of action and dose-dependent effects.³ But esmolol is contraindicated in decompensated HF, and labetalol may worsen HF.¹
Digoxin is reasonable for rate control in patients with AF and HF, in combination with other rate-controlling agents or as monotherapy if other agents are not tolerated. In RATE-AF (160 patients aged 60 years or older with permanent AF and symptoms of heart failure; 81% with LVEF ≥50%), there was no statistically significant difference in patient-reported quality of life between digoxin and bisoprolol.^2,10
IV amiodarone is the fall-back for rate control in the critically ill or decompensated-HF patient in whom beta blockers and non-DHP CCBs are ineffective or contraindicated.²
Landiolol was more effective than digoxin for controlling rapid AF/flutter in patients with LV dysfunction (NYHA III–IV, LVEF 25–50%, HR ≥120 bpm) in the J-LAND trial.⁶

Target heart rate for rate control

In the RACE II trial of 614 patients with permanent AF, lenient rate control (resting heart rate <110 bpm) was non-inferior to strict control (<80 bpm) for the composite of cardiovascular death, HF hospitalization, stroke, embolism, bleeding, and life-threatening arrhythmia at 3 years.² Consequently, a resting rate of <110 bpm is an acceptable initial target, with a stricter goal (<80 bpm at rest) reserved for persistent symptoms, deterioration of LV function, concomitant cardiac resynchronization therapy, or suspected tachycardia-mediated cardiomyopathy.⁴ Interpretation is tempered by the underrepresentation of HF patients in RACE II.²

Beta-1 selectivity and the role of landiolol

Beta blockers are not interchangeable for acute AF. A systematic review and meta-analysis of randomized trials found that efficacy depends on beta-1 selectivity: super-selective beta-1 blockers (landiolol) were superior to comparators (diltiazem and digoxin, 2 studies) for achieving target heart rate, whereas selective beta-1 blockers (metoprolol, esmolol) were inferior to diltiazem.⁸ The 2024 ESC AF guideline lists IV landiolol, amiodarone, or digoxin as options for the hemodynamically unstable patient or one with severely impaired LVEF.³ Landiolol (Rapiblyk) is FDA-approved for the short-term reduction of ventricular rate in adults with supraventricular tachycardia, including atrial fibrillation and atrial flutter.⁹

When both problems coexist

A patient with AF, a rapid ventricular response, and a genuine hypertensive emergency presents a convergent target. Esmolol appears on both lists: it is a preferred agent for acute aortic dissection and for perioperative hypertension, and IV beta blockers are Class 1 for acute AF rate control.^1,2 Landiolol is indicated for short-term reduction of ventricular rate; it does not appear in the guideline’s IV antihypertensive tables.^1,9 Two caveats govern the choice:

Decompensated heart failure or LV systolic dysfunction changes both lists at once: esmolol is contraindicated in decompensated HF, and labetalol may worsen HF;¹ IV non-DHP CCBs are a Class 3 (Harm) recommendation in moderate or severe LV systolic dysfunction² — leaving digoxin or amiodarone for rate and a dihydropyridine (clevidipine/nicardipine) or nitrate for pressure.^1,2
Not every tachycardia should be treated. In acute illness, ensure the rapid rate is not a compensatory response to hypovolemia, sepsis, or hypoperfusion before slowing it; address the underlying trigger in parallel.⁴

Frequently asked questions

Which IV drug is first-line for hypertensive emergency in aortic dissection?

Esmolol or labetalol. Beta blockade should precede any vasodilator, and the goal is SBP ≤120 mm Hg within 20 minutes.¹

Why are beta blockers contraindicated in hypertensive emergency with pulmonary edema?

The 2025 AHA/ACC comorbidity table lists beta blockers as contraindicated in acute pulmonary edema; preferred agents are clevidipine, nitroglycerin, or nitroprusside.¹

Can you give diltiazem or verapamil for AF rate control in reduced ejection fraction?

No. IV non-dihydropyridine calcium channel blockers are a Class 3 (Harm) recommendation in moderate-to-severe LV systolic dysfunction. They are first-line only when EF >40%.²

Is nicardipine or labetalol better for rapid BP control?

Trials cited by the guideline found IV nicardipine more effective than labetalol at reaching short-term BP targets, and clevidipine faster than nicardipine.¹

What heart-rate target should be used for AF rate control?

A resting rate of <110 bpm (lenient control) is an acceptable initial target based on RACE II, with a stricter goal (<80 bpm) for persistent symptoms, LV deterioration, CRT, or tachycardia-mediated cardiomyopathy.^2,4

What agent controls both AF rate and blood pressure at once?

Esmolol appears on both lists: it is a preferred agent for acute aortic dissection and for perioperative hypertension, and IV beta blockers are Class 1 for acute AF rate control.^1,2 Landiolol is a super-selective beta-1 antagonist approved for short-term ventricular-rate reduction in supraventricular tachycardia including AF and flutter;⁹ it does not appear in the guideline’s IV antihypertensive tables.¹ The critical caveat: esmolol is contraindicated in decompensated HF, labetalol may worsen HF, and IV non-DHP CCBs are a Class 3 (Harm) recommendation in moderate or severe LV systolic dysfunction, leaving digoxin or amiodarone for rate and a dihydropyridine (clevidipine, nicardipine) or nitrate for pressure.^1,2

Which rate-control drug is safest in AF with heart failure and reduced ejection fraction?

Beta blockers and digoxin — not non-dihydropyridine calcium channel blockers, which are a Class 3 (Harm) recommendation in moderate-to-severe LV systolic dysfunction.² IV amiodarone is reasonable for acute rate control in AF with HF when beta blockers or calcium channel blockers are contraindicated or ineffective.² Landiolol was more effective than digoxin for controlling rapid AF/flutter in patients with LV dysfunction in the J-LAND trial,⁶ and in RATE-AF, a trial in permanent AF with symptoms of heart failure (81% with LVEF ≥50%), low-dose digoxin matched bisoprolol for quality of life while producing fewer adverse effects.^2,10

How quickly should blood pressure be lowered in a hypertensive emergency?

Rapidly but in a controlled fashion — mean arterial pressure is generally reduced by no more than about 25% in the first hours to avoid vital-organ hypoperfusion from loss of autoregulation, except where a specific condition dictates otherwise (e.g., SBP ≤120 mm Hg within 20 minutes in acute aortic dissection).^1,7 Severe hypertension without acute target-organ damage should not receive aggressive short-term lowering or parenteral therapy at all.¹

References

Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;86(18):1567–1678. doi:10.1016/j.jacc.2025.05.007. PMID 40815242. (Section 6.2; Tables 26 and 27.) Correction in: J Am Coll Cardiol. 2026;87(23):3379, which changes the labetalol slow IV injection in Table 26 from every 2 min to 10-min intervals. doi:10.1016/j.jacc.2026.04.021. PMID 42300826.
Joglar JA, Chung MK, Armbruster AL, et al; Writing Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83(1):109–279. (Section 7.2.1, acute rate control; RACE II and diltiazem comparative data. Section 9.2, AF and heart failure; RATE-AF.) doi:10.1016/j.jacc.2023.08.017. PMID 38043043.
Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the Management of Atrial Fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314–3414. (Section 7.1.2, heart rate control in the acute setting; landiolol/amiodarone/digoxin options.) doi:10.1093/eurheartj/ehae176. PMID 39210723.
Chyou JY, Barkoudah E, Dukes JW, et al. Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association. Circulation. 2023;147(15):e676–e698. (Rate targets and the caution against reflexively slowing compensatory tachycardia.) doi:10.1161/CIR.0000000000001133. PMID 36912134.
Wigginton JG, Agarwal S, Bartos JA, et al. Part 9: Adult Advanced Life Support: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16_suppl_2):S538–S577. (Atrial fibrillation/flutter with rapid ventricular response; immediate electrical cardioversion for instability, and IV amiodarone for rate control in critically ill patients.) doi:10.1161/CIR.0000000000001376. PMID 41122884.
Syed YY. Landiolol: A Review in Tachyarrhythmias. Drugs. 2018;78(3):377–388. (Summarizing the J-LAND trial of landiolol vs digoxin in AF/flutter with LV dysfunction, NYHA III–IV, LVEF 25–50%.) doi:10.1007/s40265-018-0883-9. PMID 29470800.
Boulestreau R, Śpiewak M, Januszewicz A, et al. Malignant Hypertension: A Systemic Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2024;83(17):1688–1701. (Recommendation to reduce mean BP by no more than ~25% in the first hours to avoid cerebral hypoperfusion.) doi:10.1016/j.jacc.2024.02.037. PMID 38658108.
Perrett M, Gohil N, Tica O, Bunting KV, Kotecha D. Efficacy and safety of intravenous beta-blockers in acute atrial fibrillation and flutter is dependent on beta-1 selectivity: a systematic review and meta-analysis of randomised trials. Clin Res Cardiol. 2024;113(6):831–841. doi:10.1007/s00392-023-02295-0. PMID 37658166.
RAPIBLYK (landiolol) for injection, for intravenous use. Prescribing information. AOP Health US, LLC. NDA 217202; initial U.S. approval November 22, 2024; pediatric patients with supraventricular tachycardia added February 13, 2026. Indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter, and pediatric patients with supraventricular tachycardia (adults with normal cardiac function: start at 9 mcg/kg/min, maximum 36 mcg/kg/min; impaired cardiac function: start at 1 mcg/kg/min). DailyMed setid 411b0949-3a5e-2a4b-e063-6394a90abcbf. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=411b0949-3a5e-2a4b-e063-6394a90abcbf.
Kotecha D, Bunting KV, Gill SK, et al. Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. JAMA. 2020;324(24):2497–2508. doi:10.1001/jama.2020.23138. PMID 33351042.

Disclaimer. This page is an educational reference for licensed clinicians. It is not medical advice, does not establish a clinician–patient relationship, and does not substitute for individualized assessment. Agent selection, dosing, and blood-pressure or heart-rate targets must be tailored to the specific patient, comorbidities, hemodynamic status, and institutional resources. Verify all drug doses against current package inserts and institutional protocol, and consult the full guideline documents cited above for the complete recommendations, classes of recommendation, and levels of evidence.

This page was written and cited by the CRNA who builds Helix Anesthesia, a point-of-care reference built for the operating room — surgical cases, drug dosing, regional blocks with labeled ultrasound anatomy, and crisis checklists, all cited and available offline.

The guidance above is cited to the primary literature listed rather than to the app’s own case text. The sourcing standard is the same either way, and it is documented at how we source clinical content.

Built for the anesthesia machine, not the desk. It opens in one tap, works with no signal in an OR that has none, and shows the citation on screen beside the number rather than making you go and find it.

Free tier, no card: every calculator, every crisis checklist, the full drug library and glossary, three complete regional blocks, five complete surgical cases, and 15 AI questions a month.

Get Helix Anesthesia How we source it

Sign up for our newsletter and special offers. New answer pages, improvements to the ones already here, and the occasional offer. Nothing else, and not often.

Hemodynamics

← Clinical references for anesthesia providers — the full index for clinicians. · ← What to tell your anesthesia provider before surgery — the plain-language index of these guides. · How we source clinical content · All clinical answers